ArticleFrontiers in oncology2025
Assessing the prognostic value of serum creatinine to cystatin C ratio in stage III-IV colorectal cancer: development of a nutritional prognostic scoring system.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: For patients with stage III-IV colorectal cancer (CRC), malnutrition and poor prognosis are prevalent; however, the prognostic value of the serum creatinine to cystatin C ratio (CCR) in this setting remains uncertain. This study aims to investigate the prognostic significance of CCR and develop a nutritional prognostic scoring system based on CCR. Methods: Restricted cubic splines (RCS) were utilized to investigate the relationship between CCR and prognosis. Patients were categorized into high and low CCR groups based on RCS cut-off values and divided into quartiles (Q1 to Q4). Kaplan-Meier (KM) curves were employed for survival analysis, and multivariate Cox regression analyses were identified prognostic factors and to construct a tumor nutritional prognostic scoring system for patients. Receiver Operating Characteristic (ROC) and area under curve (AUC) were used to evaluate the scoring system. Results: The RCS analysis showed a linear relationship between CCR and prognosis (P = 0.76), with lower CCR levels correlating with higher hazard ratios (HR). Clinically, patients in the low CCR group exhibited poorer overall survival (OS), more advanced stages, and a higher proportion of deficient Mismatch Repair status. KM curves revealed that patients with higher CCR levels had better prognoses, with the best outcomes in the Q4 group and the worst in the Q1 group. After adjusting for confounding biases, TNM stage IV (HR = 2.34, 95% CI: 2.03 - 2.70), low CCR (HR = 1.16, 95% CI: 1.01 - 1.33) and CEA (HR = 1.17, 95% CI: 1.13 - 1.22) were identified as risk factors for prognosis, while Body Mass Index (BMI; HR = 0.98, 95% CI: 0.96 - 1.00) and albumin (HR = 0.99, 95% CI: 0.97 - 1.00) were protective factors. Finally, based on albumin levels, BMI, CEA, and CCR levels, a personalized nutritional prognostic scoring system was developed, to predict 1, 2, and 3-year OS, demonstrating good accuracy (AUC = 0.73) and calibration. Conclusion: CCR levels are closely related to the prognosis of stage III-IV CRC patients, with low levels linked to malnutrition and worse outcomes. We developed a novel nutritional prognostic scoring system, which holds clinical value in predicting outcomes for patients with metastatic CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.